Acorah Software Products - Accounts Production 16.5.460 false true true 31 May 2024 1 June 2023 false 2 October 2025 1 June 2024 31 May 2025 31 May 2025 10684797 R E Long I Maeda T Sakakibara T Takai S Primrose J C Howell false iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 10684797 2024-05-31 10684797 2025-05-31 10684797 2024-06-01 2025-05-31 10684797 frs-core:CurrentFinancialInstruments 2025-05-31 10684797 frs-core:Non-currentFinancialInstruments 2025-05-31 10684797 frs-core:ComputerEquipment 2025-05-31 10684797 frs-core:ComputerEquipment 2024-06-01 2025-05-31 10684797 frs-core:ComputerEquipment 2024-05-31 10684797 frs-core:FurnitureFittings 2024-06-01 2025-05-31 10684797 frs-core:PlantMachinery 2025-05-31 10684797 frs-core:PlantMachinery 2024-06-01 2025-05-31 10684797 frs-core:PlantMachinery 2024-05-31 10684797 frs-core:ShareCapital 2025-05-31 10684797 frs-core:RetainedEarningsAccumulatedLosses 2025-05-31 10684797 frs-bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 10684797 frs-bus:FilletedAccounts 2024-06-01 2025-05-31 10684797 frs-bus:SmallEntities 2024-06-01 2025-05-31 10684797 frs-bus:Audited 2024-06-01 2025-05-31 10684797 frs-bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 10684797 1 2024-06-01 2025-05-31 10684797 frs-core:UnlistedNon-exchangeTraded 2025-05-31 10684797 frs-core:UnlistedNon-exchangeTraded 2024-05-31 10684797 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-05-31 10684797 frs-core:AdditionsToInvestments frs-core:UnlistedNon-exchangeTraded 2025-05-31 10684797 frs-core:DisposalsRepaymentsInvestments frs-core:UnlistedNon-exchangeTraded 2025-05-31 10684797 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-05-31 10684797 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-05-31 10684797 frs-core:DisposalsDecreaseInProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-05-31 10684797 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-05-31 10684797 frs-bus:Director1 2024-06-01 2025-05-31 10684797 frs-bus:Director2 2024-06-01 2025-05-31 10684797 frs-bus:Director3 2024-06-01 2025-05-31 10684797 frs-bus:Director4 2024-06-01 2025-05-31 10684797 frs-bus:Director5 2024-06-01 2025-05-31 10684797 frs-bus:Director6 2024-06-01 2025-05-31 10684797 frs-countries:EnglandWales 2024-06-01 2025-05-31 10684797 2023-05-31 10684797 2024-05-31 10684797 2023-06-01 2024-05-31 10684797 frs-core:CurrentFinancialInstruments 2024-05-31 10684797 frs-core:Non-currentFinancialInstruments 2024-05-31 10684797 frs-core:ShareCapital 2024-05-31 10684797 frs-core:RetainedEarningsAccumulatedLosses 2024-05-31
Registered number: 10684797
Carus Animal Health Limited
Financial Statements
For The Year Ended 31 May 2025
Michael Price Associates Limited
Carus Animal Health Limited
Contents
Contents

| Page
--- | ---
Balance Sheet | 1
Notes to the Financial Statements | 2—4

Page 1
Carus Animal Health Limited
Balance Sheet
As At 31 May 2025
Balance Sheet
Registered number: 10684797

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 180,901 |  | 3,681
|  |  | 180,901 |  | 3,681
CURRENT ASSETS
Stocks | 6 | 65,978 |  | - |
Debtors | 7 | 404,954 |  | 656,116 |
Cash at bank and in hand |  | 1,439,716 |  | 1,461,926 |
|  | 1,910,648 |  | 2,118,042 |
Creditors: Amounts Falling Due Within One Year | 8 | (687,659 ) |  | (479,013 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 1,222,989 |  | 1,639,029
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 1,403,890 |  | 1,642,710
NET ASSETS |  |  | 1,403,890 |  | 1,642,710
CAPITAL AND RESERVES
Called up share capital | 9 |  | 37,978,070 |  | 32,098,822
Profit and Loss Account |  |  | (36,574,180 ) |  | (30,456,112 )
SHAREHOLDERS' FUNDS |  |  | 1,403,890 |  | 1,642,710

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

R E Long Director | T Takai Director
30/09/2025

The notes on pages 2 to 4 form part of these financial statements.
Page 1
Page 2
Carus Animal Health Limited
Notes to the Financial Statements
For The Year Ended 31 May 2025
Notes to the Financial Statements
1. General Information
Carus Animal Health Limited is a private company, limited by shares, incorporated in England & Wales, registered number 10684797 . The registered office is Castle Court, 41 London Road, Reigate, Surrey, RH2 9RJ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The directors and management are not aware of any material uncertainties, which may cast doubt on the company's ability to continue as a going concern. The shareholders have expressed their continuing support for the company as at the balance sheet date and for the foreseeable future.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant & Machinery | 3 years straightline
Fixtures & Fittings | 3 years straightline
Computer Equipment | 3 years straightline

After internal consideration the depreciation policy has changed during the financial year from a reducing balance to straight line policy. This has seen an increase to depreciation expense within the profit and loss for the financial year.
2.4. Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.5. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.6. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
Page 2
Page 3
Carus Animal Health Limited
Notes to the Financial Statements (continued)
For The Year Ended 31 May 2025
3. Average Number of Employees
Average number of employees, including directors, during the year was: 14 (2024: 12)
14 12
4. Tangible Assets

| Plant & Machinery | Computer Equipment | Total
--- | --- | --- | ---
| £ | £ | £
Cost
As at 1 June 2024 | - | 4,463 | 4,463
Additions | 183,306 | 8,822 | 192,128
As at 31 May 2025 | 183,306 | 13,285 | 196,591
Depreciation
As at 1 June 2024 | - | 782 | 782
Provided during the period | 12,326 | 2,582 | 14,908
As at 31 May 2025 | 12,326 | 3,364 | 15,690
Net Book Value
As at 31 May 2025 | 170,980 | 9,921 | 180,901
As at 1 June 2024 | - | 3,681 | 3,681

5. Fixed asset investments

| Unlisted
--- | ---
| £
Cost
As at 1 June 2024 | 2,307,032
Additions | 543,504
Disposals | (2,850,536 )
As at 31 May 2025 | -
Provision
As at 1 June 2024 | 2,307,032
Disposals | (2,307,032 )
As at 31 May 2025 | -
Net Book Value
As at 31 May 2025 | -
As at 1 June 2024 | -

6. Stocks

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Stock | 65,978 |  | -

Page 3
Page 4
Carus Animal Health Limited
Notes to the Financial Statements (continued)
For The Year Ended 31 May 2025
7. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Prepayments and accrued income | 85,471 |  | 495,845
Other debtors | 8,130 |  | -
VAT | 285,838 |  | 157,141
| 379,439 |  | 652,986
Due after more than one year
Other debtors | 25,515 |  | 3,130
| 404,954 |  | 656,116

8. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 300,861 |  | 185,681
Other taxes and social security | 36,442 |  | 27,188
Other creditors | 22,801 |  | 36,752
Accruals and deferred income | 327,555 |  | 229,392
| 687,659 |  | 479,013

9. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 37,978,070 |  | 32,098,822

10. Exceptional Items
Exceptional items relate to the loss on sale or close down of all group subsidiary activities.
11. Controlling Party
The ultimate controlling party is Kyoritsu Holdings Corporation.
The company is a subsidiary of Kyoritsu Holdings Corporation. The address of the parent company's registered office is
6-5, 1-chome, Kudan-minami, Chiyoda-ku, Tokyo 102-0074 Japan.
12. Lease Agreements
At the year end the company had total commitments under operating leases of £219,701 (2024 - £35,995) in relation to office and lab space.
13. Audit Information
The auditor's report on the accounts of Carus Animal Health Limited for the year ended 31 May 2025 was unqualified.
The auditor's report was signed by Samuel Ketcher FCCA (Senior Statutory Auditor) for and on behalf of Xeinadin Audit Limited , Statutory Auditor.

Xeinadin Audit Limited Chartered Accountants, Statutory Auditor 12 Conqueror Court Sittingbourne Kent ME10 5BH

Page 4